WO2019209227A2 - Solid oral formulations comprising herbal extracts - Google Patents
Solid oral formulations comprising herbal extracts Download PDFInfo
- Publication number
- WO2019209227A2 WO2019209227A2 PCT/TR2018/050920 TR2018050920W WO2019209227A2 WO 2019209227 A2 WO2019209227 A2 WO 2019209227A2 TR 2018050920 W TR2018050920 W TR 2018050920W WO 2019209227 A2 WO2019209227 A2 WO 2019209227A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- formulation
- formulation according
- amount
- propolis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Definitions
- the present invention relates to an herbal formulation comprising propolis extract and berberis vulgaris extract for providing treatment in various respiratory diseases such as cold, cough, allergic asthma, seasonal allergic rhinitis, bronchitis, pharyngitis, laryngitis and pneumonitis.
- Herbal medical products have long been in use for the treatment or prophylaxis of respiratory diseases.
- these diseases which are typically caused by viruses, bacteria, and/or fungi
- it is quite significant both to eradicate these harmful organisms and to boost the immune system of the affected individual.
- the immune system is comprised of processes providing protection against diseases, as well as recognizing and eliminating the pathogenic and tumor cells in a living being.
- the system scans the organism against any kind of foreign substances, entering or contacting the former, from viruses to parasitic worms of a wide variety, and distinguishes them from the organism's own healthy cells and tissues.
- the immune system can even distinguish substances with very similar features from each other to such an extent that even proteins having a different amino acid can be distinguished from the equivalents thereof.
- the function of the immune system is primarily to prevent harmful foreign substances from entering the respective organism, or upon entry, to retain the substances at the place of entry, or to prevent or delay their spreading therein.
- Berberis vulgaris berries are edible and rich in vitamin C.
- Berberine is the main active alkaloid with a benzyl tetra hydroxy quinoline chemical structure which can be found in all part of berberis vulgaris especially in its fruit (barberry). It is odorless but with a bitter taste powder which is sparingly soluble in methanol, slightly soluble in ethanol and very slightly soluble in water.
- Propolis is one of the most important bee products. Besides its antibacterial, antifungal, antiviral features, a great number of beneficial biological activities such as anti inflammatory, anti-ulcer, local anesthetic, anti-tumor and immunity stimulant properties popularizes its usage in medicine, apitherapy, health nutrition and biocosmetic fields. It comprises 150 chemical compounds, more than 20 mineral substances, beeswax, resin and pollen. In chemical terms, propolis comprises a wide variety of extremely complex and potent terpenes, benzoic acids, caffeic acids, cinnamic acids, and phenolic acids. It has a high flavonoid content.
- Propolis is one of the most powerful antibiotics found in nature. It is rich in terms of amino acids and trace metals, has a very high vitamin content and contains at least 38 valuable bioflavonoids. It is an invaluable antioxidant based on its high bioflavonoid content. It was demonstrated to inactivate at least 21 bacteria species, 9 fungi species, 3 protozoa (including giardia), and a wide spectrum of viruses.
- propolis may be used as an effective anti-inflammatory agent against aphtha and other gingiva wounds and peptic ulcer.
- propolis is two times more effective than acyclovir which is the conventional anti-viral drug in herpes treatment.
- MCF-7 human breast cancer cells
- Pelargonium sidoides African Geranium, Umckaloabo
- Pelargonium sidoides African Geranium, Umckaloabo
- Pelargonium sidoides has antiviral properties strengthening the immune system. It further has both antibacterial effects and antioxidative properties against some bacteria. Apart from that, it was also reported to boost the immune system of the respective organism and to have expectorant action by increasing the ciliary beat frequency of respiratory epithelial cells.
- Echinacea purpurea the purple coneflower, is a plant species widely used in the prophylaxis and/or treatment of infection, cold, cough, bronchitis, flu, in the treatment of infection of the urinary system, in the treatment of the sore throat and toothache, in boosting the immune system, and externally, in the treatment of snakebite, eczema, psoriasis, acne, wounds and burns.
- Echinacea purpurea is known to have immunostimulant, anti-inflammatory, antibacterial, antiviral, antifungal, anticancer, cicatrizant activities.
- Echinacea purpurea supports the production of interferon, thereby strengthening the defense system of the respective organism.
- Interferon activates the natural killer cells and induces these cells to bind to and destroy infected cells or tumor bearing cells.
- Interferon is effective in releasing the enzymes destroying the genetic structure of viruses and inhibiting their reproductive and spreading capabilities.
- Ginseng root is harvested after a cultivation period of 6 years and this part of the plant is used for therapeutic purposes. It comprises saponins (dammaran and oleanan derivatives; ginsenosites), polyacetylene derivatives and polysaccharides.
- saponins dammaran and oleanan derivatives; ginsenosites
- polyacetylene derivatives polysaccharides.
- the effects of Ginseng on the body are not local, and thus, one of the benefits of Ginseng is that it strengthens the entire body and helps in balancing entire body systems.
- Ginseng is an antioxidant and an important immunity system improver which increases the number of immunity system cells in the body. It is useful in the treatment of bronchitis, asthma and the circulation problems.
- the flu risk of people who are administered 200mg ginseng root capsules twice a day reduced by 31%. In the laboratory and animal experiments, it is found that it is effective against prostate, stomach, kidney, liver, large intestine, brain and lung
- Ginger (Zingiber officinale) is also called “warming herb” and used for a long time as an important medical herb. It comprises essential oils with ether comprising Zingiberene, Zingiberol, Gingerol and Shogol. The essential oils contained which are mixed with terpenoids give the special taste and scent of ginger. The bitter substances without essential oils which make the mouth feel warm are gingerol and zingeron.
- Ginger has a wide area of usage. Ginger is preventive against cancer based on stopping the Epstein-barr virus activity. 6-gingerol and 6-paradol, among the active substances of ginger, are effective in stopping promyelocytic leucaemia by disturbing the DNA synthesis. It also has anti-inflammatory effect, is effective against arthritis and headache, and is bacteriostatic. It is used against nausea, spasm and fever in kids. Based on its antiseptic effect, it is used against stomach and intestine infections and even against food poisoning. It also prevents the coagulation of the blood and has blood thinning effect. It supports the cardiovascular system by making the platelets less adherent, this in turn causes a decrease in the problems of the circulation system. It is appetizing and can also be used against constipation.
- Honey is the natural product processed by honeybees from flower nectars or plant secretions, by aid of their own secretions.
- Honey is a nutritious, sweet and healthy food, and minor components of honey include proteins (0.25-0.5%), organic acids, aminoacids, vitamins, flavonoids and water.
- the amount of water in honey is between 15.00% and 30.00% by weight.
- Honey has been used for treatment of microbial infections since ancient times. In recent years there has been a resurgence of interest in the therapeutic efficacy of honey. While it may naturally have a long shelf life, heating and cooling the spread too many times can cause it to lose its colour and aroma. Shelf-life of honey depends on botanical origin as well as processing.
- TR2014/02396B relates to process for producing solid honey which has water in an amount less than 1.00% by weight.
- EP2387329B1 relates to a honey product comprising honey having a low moisture content.
- Honey is an excellent source of easily digestible sugars. It is largely composed of glucose and fructose, monosaccharides that are rapidly absorbed and metabolized by the organism. It also contains volatile components which makes it a very palatable ingredient. Honey may contain enzymes, pollen and propolis which have been recognized as having excellent health benefits.
- a product can be a "medical" product only by having these elements.
- a product prepared from a herbal source In order for a product prepared from a herbal source to be a medical product, it has to be prepared from an efficient and standardized extract, to have established pharmacological, clinical outcomes and toxicological data, and a determined stability. Therefore, it bears great significance to have a good stability for a product, produced from herbal sources, to be used in the treatment and prevention of diseases, or in the alleviation and/or elimination of the symptoms thereof.
- the physical properties are taken into account in the evaluation of the physical stability of a product, particularly the taste, scent, color, clarity, uniformity, etc. of a product, also considerably influence the patient compliance. For this reason, when a novel formulation is developed, besides aiming a formulation of good physical stability, the physical properties of this formulation should be made ideal to provide high patient compliance.
- the physical properties and the physical stability of a formulation are influenced directly from the characteristic properties of herbal agents contained therein.
- Some aspects of herbal agents contained in a formulation such as having a bad taste, a bad scent, a bad color and similar physical properties, becoming easily oxidized, and providing a suitable medium for the reproduction of microorganisms negatively influence the physical properties and physical stability of that formulation.
- a formulation comprises a combination of herbal agents, a correct selection of the herbal agents bears great importance, since more than one herbal agent present in the same formulation is capable to mutually affect their respective properties.
- the main object of the present invention is to obtain formulations which have improved physical stability, comprising propolis extract and berberis vulgaris extract.
- Another object of the present invention is to provide formulations with a significantly improved stability, as well as the excellent long-term stability.
- Another object of the present invention is to provide formulations for providing treatment in various respiratory diseases such as cold, cough, allergic asthma, seasonal allergic rhinitis, bronchitis, pharyngitis, laryngitis and pneumonitis.
- Another object of the present invention is to provide formulations which have increased quality, reliability, and shelf life as a result of an improved physical stability.
- Another object of the present invention is to provide formulations comprising berberis vulgaris extract and propolis extract, which both maintains the physical stability and has improved physical properties as a result of using suitable excipients.
- Yet another object of the present invention is to develop formulations which are capable of providing an easy administration accompanied by an increased patient compliance and convenience.
- a further object of the present invention is to provide a simple, cost-efficient, and time saving process for preparing formulations comprising berberis vulgaris extract and propolis extract.
- the present invention discloses a novel, stable, bioavailable, oral compositions for the oral administration of extracts of propolis and berberis vulgaris.
- the maintenance of the physical stability of a pharmaceutical product can be ensured if no change occurs in the physical structure of that product. Therefore, whether the physical stability is maintained or not is assessed by determining changes in various physical properties of the product during formulation development process. Properties such as the color, scent, taste, pH, clarity, viscosity, homogeneity, density are among the physical properties of a pharmaceutical are the basic physical properties playing role in the assessment of the physical stability thereof.
- a formulation according to the present invention comprises propolis extract and berberis vulgaris extract.
- the formulation is administered by oral, parenteral, ocular, nasal, buccal, sublingual and topical route.
- the formulation is administered by oral route.
- the formulation is in the form of lozenges, tablets, effervescent tablets, effervescent sachets, orally disintegrating tablets, sublingual tablets, buccal tablets, capsules or syrup. In one preferred embodiment, the formulation is in the form of lozenges.
- the composition is maintained in contact with the mouth and/or throat for a sufficient length of time that reduction of the severity or presence of one or more symptoms of the cold is achieved.
- the lozenges of this invention may be of any shape.
- the composition is maintained in contact with the mouth and/or throat for a sufficient length of time that infection by cold viruses is prevented.
- the amount of propolis extract is between 0.005% and 10.00%, preferably between 0.01 % and 5.00%, more preferably 0.01% and 1.00% by weight of the formulation.
- the amount of berberis vulgaris extract is between 0.005% and 10.00%, preferably between 0.01% and 5.00% and more preferably between 0.01% and 0.50% by weight of the total formulation.
- the weight ratio of propolis extract to berberine is between 0.01 and 100, preferably between 0.10 and 10.00 and more preferably between 0.2 and 2.0. It was observed that this had a synergistic effect on the physical stability of said formulation. Thus, by providing an improved physical stability; the quality, reliability, and the shelf life of the formulation according to the present invention are increased.
- the formulation further comprises at least one additional herbal extract which is selected from the group comprising pelargonium sidoides, ginseng, glycyrrhiza glabra, echinacea purpurea, tilia, zingiber officinale, citrus junos, licorice, hedera helix, ginkgo biloba, turmeric, capsicum, sage, rosemary, maca, rhodiola or mixtures thereof.
- additional herbal extract which is selected from the group comprising pelargonium sidoides, ginseng, glycyrrhiza glabra, echinacea purpurea, tilia, zingiber officinale, citrus junos, licorice, hedera helix, ginkgo biloba, turmeric, capsicum, sage, rosemary, maca, rhodiola or mixtures thereof.
- At least one additional herbal extract is selected from the group comprising pelargonium sidoides, ginseng, glycyrrhiza glabra, echinacea purpurea, tilia, zingiber officinale, citrus junos or mixtures thereof.
- the stability and therapeutic effectiveness of the composition is influenced by the choice of the herbal extracts, the herbal extracts which are used in this present invention, are very important.
- herbal extracts are pelargonium sidoides, ginseng, glycyrrhiza glabra, echinacea purpurea, tilia and zingiber officinale.
- At least one additional herbal extract is pelargonium sidoides.
- the amount of pelargonium sidoides is between 0.10% and 10.00%, preferably between 0.20% and 5.00% and more preferably between 0.20% and 2.00% by weight of the formulation.
- the formulation further comprises dried honey.
- using honey in solidified form also increases the stability of the formulation.
- dried honey instead of honey, improves the physical stability of the product.
- the amount of dried honey is between 25.00% and 99.00%, preferably between 50.00% and 99.00%, more preferably between 75.00% and 99.00% by weight of the total formulation.
- At least one additional herbal extract is zingiber officinale.
- the amount of zingiber officinale is between 0.005% and 10.00%, preferably between 0.01% and 5.00%, more preferably between 0.01 % and 1.00% by weight of the total composition.
- At least one additional herbal extract is glycyrrhiza glabra.
- the amount of glycyrrhiza glabra is between 0.01 % and 10.00%, preferably between 0.05% and 5.00%, more preferably between 0.05% and 0.50% by weight of the total composition.
- At least one additional herbal extract is echinacea purpurea.
- the amount of echinacea purpurea extract is between 0.01 % and 10.00%, preferably between 0.05% and 5.00%, more preferably between 0.05% and 0.50% by weight of the total composition.
- At least one additional herbal extract is tilia.
- the amount of tilia extract is between 0.01% and 10.00%, preferably between 0.05% and 5.00%, more preferably between 0.05% and 0.50% by weight of the total composition.
- All plant extracts comprised in the content of the formulation within the scope of the present invention can be obtained from the shell, leaf, flower, root or seed of respective plants.
- the composition further comprises zinc sulfate monohydrate.
- Zinc is used for treating the common cold and recurrent ear infections, and preventing lower respiratory infections. It can also help shorten the length of colds.
- the composition may further comprise silver solution.
- Silver solution is used in the treatment and alleviation of the symptoms of cold.
- Flavouring agent used according to the present invention is selected from the group comprising but not limited to, eucalyptus, menthol, peppermint, lime, apple, cinnamon, chocolate, vanillin and fruit essences such as cherry, orange, strawberry, grape, tutti frutti.
- the amount of the flavouring agent is between 0.05% and 5.00% by weight of the total composition.
- the flavouring agent is eucalyptus.
- Eucalyptus species which have analgesic and anti-inflammatory activities are also widely used in modern cosmetics, food, and pharmaceutical industries. Since eucalyptus has antibacterial and anticeptic qualities, it has been shown to protect against microbial growth that can promote a host of different symptoms and diseases in the body. In this present invention, one important reason that the inventors preferably use eucalyptus is that it creates a cooling and refreshing effect.
- eucalyptus When eucalyptus is used as the flavouring agent, it is observed that it shows a supporting effect for said formulation due to the refreshing, cooling and smoothening effect of scent and the patients administered with said formulation feels instant relief and alleviation of symptoms, thus, it helped them feel better within a shorter period of time.
- said formulation comprises;
- said formulation comprises; a) propolis extract in the amount of between 0.005% and 10.00%
- berberis vulgaris extract in the amount of between 0.005% and 10.00%
- pelargonium sidoides extract in the amount of between 0.10% and 10.00%, by weight of the formulation.
- said formulation comprises;
- propolis extract in the amount of between 0.005% and 10.00%
- said formulation comprises;
- said formulation comprises;
- said formulation comprises;
- said formulation comprises;
- said formulation comprises;
- At least one additional herbal extract which are selected from the group comprising pelargonium sidoides, ginseng, glycyrrhiza glabra, echinacea purpurea, tilia, zingiber officinale, berberis vulgaris, citrus junos (yuzu)
- said formulation comprises;
- At least one additional herbal extract which are selected from the group comprising pelargonium sidoides, ginseng, glycyrrhiza glabra, echinacea purpurea, tilia, zingiber officinale, berberis vulgaris, citrus junos (yuzu)
- said formulation comprises:
- said formulation comprises: a. propolis extract 0.005-10.00%
- the solid oral compositions mentioned above are prepared by following these steps: a. Preparing dried honey by a physical method in which microwave or heat is used b. Weighing each herbal extract, zinc sulfate monohydrate, silver solution and
- the solid oral composition comprises one lubricant.
- the solid oral composition can be prepared by following these steps: a. Mixing all ingredients
- the effervescent tablet composition mentioned above is prepared by following these steps: a. Mixing all ingredients except for sodium stearyl fumarate
- Example 8 Tablet or capsule
- the tablet or capsule composition mentioned above is prepared by following these steps: a. Mixing dried honey, the herbal extracts, propolis extracts, zinc sulfate
- the oral solution/syrup composition mentioned above is prepared by following these steps: a. Mixing water, trisodium citrate dihydrate and citric acid monohydrate to form the tampon citrate
- the oral solution/syrup composition mentioned above is prepared by following these steps:
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2017/22959A TR201722959A2 (tr) | 2017-12-29 | 2017-12-29 | Bi̇tki̇sel ekstreler i̇çeren kati oral formülasyonlar |
TR2017/22959 | 2017-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019209227A2 true WO2019209227A2 (en) | 2019-10-31 |
WO2019209227A3 WO2019209227A3 (en) | 2020-01-23 |
Family
ID=67900929
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2018/050920 WO2019209227A2 (en) | 2017-12-29 | 2018-12-27 | Solid oral formulations comprising herbal extracts |
PCT/TR2018/050927 WO2019199260A2 (en) | 2017-12-29 | 2018-12-28 | Formulations comprising herbal extracts |
PCT/TR2018/050928 WO2019209229A2 (en) | 2017-12-29 | 2018-12-28 | Topical formulations comprising herbal extracts |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2018/050927 WO2019199260A2 (en) | 2017-12-29 | 2018-12-28 | Formulations comprising herbal extracts |
PCT/TR2018/050928 WO2019209229A2 (en) | 2017-12-29 | 2018-12-28 | Topical formulations comprising herbal extracts |
Country Status (2)
Country | Link |
---|---|
TR (3) | TR201722959A2 (tr) |
WO (3) | WO2019209227A2 (tr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3115683A1 (fr) * | 2020-11-04 | 2022-05-06 | Bobs Silver | Composition antiseptique pour administration nasale |
WO2022096605A1 (fr) * | 2020-11-04 | 2022-05-12 | Bobs Silver | Composition antiseptique |
FR3124378A1 (fr) * | 2021-06-24 | 2022-12-30 | Bobs Silver | Composition antiseptique pour administration nasale |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2716162C1 (ru) * | 2019-11-19 | 2020-03-06 | Федеральное государственное бюджетное учреждение науки Федеральный научный центр "Владикавказский научный центр Российской академии наук" (ВНЦ РАН) | Способ лечения хронического генерализованного пародонтита легкой степени тяжести |
WO2021221577A2 (en) * | 2020-04-27 | 2021-11-04 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Formulations of food supplement comprising natural sweetener |
CN112587487B (zh) * | 2020-11-30 | 2022-08-16 | 建昌帮药业有限公司 | 一种松果菊苷口崩片及制备方法 |
CN113481612B (zh) * | 2021-07-02 | 2022-06-28 | 南通大学 | 一种纳米纤维膜复合面料的制备工艺 |
IT202200004958A1 (it) * | 2022-03-16 | 2023-09-16 | Neilos S R L | “Composizione nutraceutica o farmaceutica per il benessere renale” |
CN115428869B (zh) * | 2022-09-02 | 2024-01-05 | 南京农业大学 | 一种改善肉鸡肠道健康的生物制剂及其制备方法和应用 |
GB2623801A (en) * | 2022-10-27 | 2024-05-01 | Alex Fabian Smith | Composition and method for reducing negative taste sensations of propolis preparations |
GR1010684B (el) * | 2023-04-12 | 2024-05-13 | Ιουλια Κλεωνος Τσετη | Συνθεση για την καταπραϋνση της στοματοφαρυγγικης κοιλοτητας και του λαιμου και την ενισχυση του ανοσοποιητικου συστηματος |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1274796B (it) * | 1994-12-23 | 1997-07-24 | Stefano Verardi | "cerotto per assorbimento transcutaneo a rilascio controllato di estratti di sostanze naturali" |
US6197305B1 (en) * | 1998-01-05 | 2001-03-06 | Farmo-Nat Ltd. | Anti-fungal compositions with prolonged activity |
WO2006079109A2 (en) * | 2005-01-21 | 2006-07-27 | Rdx Technologies, Inc. | Non-toxic antimicrobial compositions and methods using pro-oxidative polyphenols and antioxidants |
EP1685875A1 (en) * | 2005-01-28 | 2006-08-02 | Gumlink A/S | Multi functional oral care chewing gum |
EA201590568A1 (ru) * | 2012-10-17 | 2015-09-30 | Монтеро Гида Санайи Ве Тиджарет А.С. | Составы, содержащие экстракты растений |
EP2937077B1 (en) * | 2014-04-24 | 2021-10-06 | Montero Gida Sanayi Ve Ticaret A.S. | Oral liquid formulations comprising herbal extracts |
US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
CA2973217A1 (en) * | 2015-02-11 | 2016-08-18 | The Fix, Llc | Compositions and methods for combination ingredient delivery |
CN104996994A (zh) * | 2015-04-24 | 2015-10-28 | 劲膳美生物科技股份有限公司 | 慢性阻塞性肺疾病特定全营养配方食品 |
CN106727990A (zh) * | 2017-02-14 | 2017-05-31 | 哈尔滨市第医院 | 口腔护理液及其制备方法 |
CN107510778B (zh) * | 2017-09-01 | 2020-10-09 | 河南科技大学 | 一种清肺防霾饮及其制备方法 |
-
2017
- 2017-12-29 TR TR2017/22959A patent/TR201722959A2/tr unknown
-
2018
- 2018-04-05 TR TR2018/04828A patent/TR201804828A2/tr unknown
- 2018-07-12 TR TR2018/09956A patent/TR201809956A2/tr unknown
- 2018-12-27 WO PCT/TR2018/050920 patent/WO2019209227A2/en active Application Filing
- 2018-12-28 WO PCT/TR2018/050927 patent/WO2019199260A2/en active Application Filing
- 2018-12-28 WO PCT/TR2018/050928 patent/WO2019209229A2/en active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3115683A1 (fr) * | 2020-11-04 | 2022-05-06 | Bobs Silver | Composition antiseptique pour administration nasale |
WO2022096605A1 (fr) * | 2020-11-04 | 2022-05-12 | Bobs Silver | Composition antiseptique |
FR3124378A1 (fr) * | 2021-06-24 | 2022-12-30 | Bobs Silver | Composition antiseptique pour administration nasale |
Also Published As
Publication number | Publication date |
---|---|
WO2019199260A2 (en) | 2019-10-17 |
WO2019209229A2 (en) | 2019-10-31 |
TR201804828A2 (tr) | 2019-07-22 |
WO2019209227A3 (en) | 2020-01-23 |
WO2019209229A3 (en) | 2020-01-30 |
TR201722959A2 (tr) | 2019-07-22 |
TR201809956A2 (tr) | 2019-07-22 |
WO2019199260A3 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019209227A2 (en) | Solid oral formulations comprising herbal extracts | |
Shikov et al. | Medicinal plants of the Russian Pharmacopoeia; their history and applications | |
EP2908833B1 (en) | Formulations comprising herbal extracts | |
US20090155392A1 (en) | Methods and Systems for Sublingual Guarana Administration | |
EP2908834B1 (en) | New formulations comprising plant extracts | |
US10111912B2 (en) | Herbal formulations | |
Fugh-Berman | The 5-minute herb and dietary supplement consult | |
EP2512444B1 (en) | Mixtures of plants in spagyric mother tincture for dry cough in babies | |
EP2908835B1 (en) | Stable formulations | |
WO2019209228A2 (en) | Solid oral compositions comprising dried honey and herbal extracts | |
CN110652552A (zh) | 一种伤口愈合配方及制备方法 | |
KR101910013B1 (ko) | 한약재 추출물(socg)을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
FR3070261A1 (fr) | Produit de combinaison pour soulager les symptomes lies aux infections des voies respiratoires superieures | |
Idreess et al. | Turmeric: An important medicinal plant in the treatment of many diseases: A review Study | |
WO2022108540A1 (en) | An herbal oral composition comprising natural ingredients | |
WO2021221577A2 (en) | Formulations of food supplement comprising natural sweetener | |
KR0185538B1 (ko) | 종합감기약 및 그의 제조방법 | |
EA021203B1 (ru) | Композиция на основе корицы и базилика для лечения или профилактики инфекций мочевыводящих путей и способ ее получения | |
Murugavel | Preclinical Safety Evaluation of Rasa Karpoora Kuligai | |
Mihail | Herbal, traditional and alternative remedies | |
CN109480272A (zh) | 一种治疗心肾的枣仁沙棘养生枣及其制备工艺 | |
PL238162B1 (pl) | Kompozycja zawierająca mieszaninę ekstraktów roślinnych | |
PL234024B1 (pl) | Preparat wspomagający leczenie schorzeń górnych dróg oddechowych i wzmacniający naturalną odporność organizmu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18916731 Country of ref document: EP Kind code of ref document: A2 |